

Our Investment Case



About us ...




"Over 20 years ago in a local pharmacy in Cologne, Germany, a young pharmacist had the idea to digitise the family business. Shop Apotheke was born. Fast forward to today, and Redcare is *Europe's leading online pharmacy*."



Innovation is in our DNA.



From humble beginnings to becoming healthcare experts.



Opening of new distribution

German roots, <u>European footprint</u>.



We are building the <u>one-stop pharmacy</u> of the future.



At our core, we are a pharmacy, combining OTC, BPC and Rx offerings.

We operate a pure B2C model and are customer centric.



Our customer-centric solutions are realised through a scalable platform model that is driven by digital innovation.



Our goal is to be the market leader in all our countries.



Our <u>one-stop</u> <u>pharmacy</u>.



MARKETPLACE

Greater assortment in Germany and Austria





MEDICATION MANAGEMENT

MyTherapy by smartpatient



OWN BRANDS

BEAVITA • nu3 • SKINTIST • Redcare



SAME-DAY DELIVERY

- Now! in Germany, Austria and Belgium
- As well as classic delivery (1-2 days), GoPuls (< 1 hour)



APPS

- Putting the pharmacy in the customer's pocket
- Now also offering CardLink in Germany for Rx



The <u>leading online brand</u>.



APPAREL

ELECTRONICS

PHARMA







OFFLINE





No significant offline brand in Continental Europe



Redcare Pharmacy <u>FY2023</u>.



10.8 Mil.
Active customers



29.4 Mil.

Orders



€ 1.8 bn Revenue



440 Mil.

Site visits



85%

Repeat orders



24.5%

Gross margin



71

Net Promoter Score (NPS)



€ 59.40

Avg. shopping basket size



3%

Adj. EBITDA margin



Redcare Pharmacy <u>H1</u> <u>2024</u>.



11.6 Mil. Active customers



17.6 Mil

Orders



€ 1,121 Mil.

Revenue



252.3 Mil.

Site visits



87%

Repeat orders



23.4%

Gross margin



69

Net Promoter Score (NPS)



€ 59.33

Avg. shopping basket size



2.4%


Adj. EBITDA margin




Our investment case.



A <u>large</u> and <u>attractive</u> market.



- · Significantly large pharmaceutical retail market.
- Largely untapped by online pharmacies; potential for increased penetration.
- Highly fragmented, requiring local knowledge and expertise.
- Undifferentiated products highly suitable for online retail, where convenience and price matter.
- Aging population.
- Increased prevalence of chronic illnesses.
- Attractive unit economics.



Sources: Grand View Research, IQVIA Trends in e-Commerce White Paper



<u>Germany:</u>


the largest market in Europe.

<u>Attractive</u> and <u>large market</u> with total revenue of over € 66 billion in 2023, of which € 61 billion from drug sales.

Prescription drug market size of € 55,7 billion.

- Germany is a mature online market, exhibiting a high online share of OTC sales (23% by 2023), especially:
 - > for chronic diseases;
 - > high priced medication;
 - > sensitive or confidential category medication.
- Rx online sales still ~ 1%.
- Rx attractive unit economics: high value, lightweight package; low return rate.

 Some 12 million Germans suffer from a chronic respiratory illness.



 One in three between the ages of 75 – 80 take more than 8 prescribed medications.

> Rx online *Allowed*

OTC online Allowed





85 million

Sources: ABDA, EAEP, Statista, Eurostat




Germany:

once-in-a-lifetime <u>opportunity</u>.




Redcare Pharmacy has a leading position

- Online Rx sales have been allowed since 2004.
- The e-prescription became mandatory in 2024, finally opening up full access to this large market.
- There is a ban on third-party ownership of pharmacies and the regulatory landscape is complex.
- As an example, in Sweden, online penetration is now at 13.4% (Rx).




- Germany is our oldest, largest market.
- We have a strong, established and trusted brand.
- We are a pharmacy, not just an online shop.
- We offer a large assortment of Rx, OTC & BPC, at attractive prices (OTC & BPC).
- We are e-pharmacy experts who mine data and continuously improve our customer-centric solutions.
- Our modern logistics centre in the Netherlands has a large capacity and is ideally located.








Opportunities in other markets.














Sources: ABDA, EAEP, Eurostat



Holding the key

to Europe's pharmacy market.



Growth.

More to come from:

- Demographic changes in Europe.
- More chronic conditions among all age groups.
- Health awareness. higher health expenditure.
- Policy changes (enabling mail-order Rx)
- > Increased digitisation.



Expertise.

Over 20 years' experience and a scalable platform model offering:

- Complementary services and benefits.
- Customised experience for various use-cases.
- Access and convenience 24/7.



Profitability.

Mid- to long-term, adj. EBITDA of >8%

- > Scale (International).
- Operational and overhead efficiencies.
- Media income.
- Marketplace.
- > Electronic script in Germany.



Our online journey is just getting started.



₹ Redcare



We are AAA

(MSCI ESG rating)

and "low risk"



(Morningstar Sustainalytics)






Financial & KPI Appendix.

Historical:


revenues and earnings.



Revenue (in millions of euros)




Gross profit margin (in millions of euros)





Summary FY2023: revenues and earnings.



\sim	
$\sim \Delta$	
\mathbf{u}	LLU

Rx € 457.3 Mil.

Non-Rx € 996.3 Mil. **INTERNATIONAL**

Non-Rx € 345.2 Mil. **GROUP**

€ 1,798.8 Mil.

GROSS PROFIT (margin)

EBITDA ADJ. EBITDA ADJ. EBITDA MARGIN € 355.7 Mil.

DACH

€ 68.1 Mil.

€ 76.6 Mil.

5.3%

€ 84.7 Mil.

€ -28.1 Mil.

€ -23.1

-6.7%

€ 440.4 Mil. 24.5%


€ 40.0 Mil.

€ 53.5 Mil.

3.0%



H1 2024: fast growth in both segments.





Summary H1 2024: revenues and earnings.

MediService included since mid-Q2 2023, leading to mixed impact on gross profit and selling and distribution margins when comparing year over year.

	Year over Year		Year over Year			
in millions of euros, <u>adjusted numbers</u>	Q2 2023	Q2 2024	Better or (worse)	H1 2023	H1 2024	Better or (worse)
Sales	420	561	33.5%	792	1,121	41.5%
Gross profit margin	25.4%	23.4%	(2) pp	26.5%	23.4%	(3.1) pp
Selling & distribution margin	(19.3)%	(17.8)%	1.5 pp	(20.8)%	(18.1)%	2.7 pp
Administrative cost margin	(2.9)%	(2.9)%	0.0 pp	(2.9)%	(2.9)%	0.0 pp
Adj. EBITDA margin	3.2%	2.7%	(0.5) pp	2.8%	2.4%	(0.4) pp
Adj. EBITDA	13	15	2	22	27	5
EBITDA	11	14	3	15	25	10



Guidance FY 2024.

Total net sales

€ 2.35 to € 2.5 bn

Total net sales growth of

30 % to 40 %



Non-Rx sales growth of

20 % to 25 %

Adj. EBITDA margin in the range of

1.2 % to 2.2 %




Key Performance Indicators: non-financial.

	2021	2022	2023
Page visits	279,996,725	347,765,913	439,676,007
Mobile page visits	198,769,379	251,718,600	330,088,835
Ratio mobile	71 %	72 %	75 %
Orders	19,712,658	23,421,138	29,413,020
Repeat orders	82 %	83 %	85 %
Return rate	0.72 %	0.73 %	0.78 %
Active customers	7,875,297	9,311,375	10,848,777
Average shopping basket	€ 61,16	€ 58,58	€ 59,40



Key Performance Indicators: non-financial.

	H1 2023	H1 2024
Page visits	220,110,389	252,308,987
Mobile page visits	165,558,858	194,796,589
Ratio mobile	75 %	77 %
Orders	14,616,242	17,602,788
Repeat orders	84 %	87 %
Return rate	0.77 %	0.74 %
Active customers	10,150,870	11,555,549
Average shopping basket	€ 58,41	€ 59,33





Thank You!





Investor Relations

investors@redcare-pharmacy.com

